Eradivir announces Phase 2 human challenge study of EV25 in healthy adults infected with influenza
Business Announcement
Updates every hour. Last Updated: 25-May-2025 23:09 ET (26-May-2025 03:09 GMT/UTC)
The European Medicines Agency and Belgium’s Federal Agency for Medicines and Health Products have approved a Phase 2 challenge study on EV25, an antiviral therapeutic from Eradivir. The approval follows the successful completion of a Phase 1 study on EV25. Based on the preliminary Phase 1 safety results, a safety review committee comprising study staff and independent physicians concluded the compound was well tolerated by participants.
Personalized nutrition (PN) has gained popularity in recent years as a customized approach to health outcomes. PN combines biomedical, genetic, and lifestyle data to provide individualized recommendations, and a plethora of companies offer various forms of health screenings, apps, programs, products, and diet advice. The Personalized Nutrition Initiative at the University of Illinois Urbana-Champaign, together with their external partners, hosted two workshops for PN practitioners and experts, aimed at establishing guidelines and setting up best practices for the field. The workshop findings were recently published in two journal articles.